ClinicalTrials.gg
CompletedNCT00654394Updated Mar 16, 2009

Progression of Carotid Artery Atheroma in Moderately Hypercholesterolemic Subjects

A Phase 3 interventional study of Rosuvastatin in Carotid Artery Stenosis and Hypercholesterolemia, sponsored by AstraZeneca. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2009-03-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to examine the changes in the carotid artery when subjects receive high or low doses of rosuvastatin.

02

Conditions studied

  • Carotid Artery Stenosis
  • Hypercholesterolemia

Keywords

  • Cholesterol
  • Carotid Artery Stenosis
  • Hypercholesterolemia
  • Rosuvastatin
  • Crestor
03

In context

Carotid Stenosis

368 studies on the registry are indexed under Carotid Stenosis; 87 are open to participants now.

This study's planned enrollment of 200 is above the median of 102 across 192 interventional studies indexed under Carotid Stenosis.

Browse Carotid Stenosis studies →

Lead sponsor

AstraZeneca is the lead sponsor of 3,504 studies on the registry; 274 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fasting blood low density lipoprotein cholesterol level as defined by the protocol
  • Diagnosed carotid arterial stenosis

Exclusion criteria

Exclusion Criteria:

  • The use of lipid lowering drugs or dietary supplements after Visit 1.
  • Heavy or total occlusion of the carotid artery or recent stroke
  • Uncontrolled hypertension, hypothyroidism, alcohol or drug abuse
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
200 participants (estimated)

Study arms

  • Experimental
    1

    Drug: Rosuvastatin

Interventions

06

What researchers measure

Primary outcomes

  1. Changes in carotid wall volume as measured by MRI scan

    Time frame: At 40 weeks and 104 weeks

Secondary outcomes

  1. Safety: adverse events & abnormal laboratory markers

    Time frame: 2 weekly for first 4 weeks then 4 weekly

  2. Other changes in the structure and composition of the carotid arterial wall as defined in the protocol.

    Time frame: At 40 weeks and 104 weeks

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2000 and a completion of Aug 2004. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2008
First posted
Apr 8, 2008
Start
Jan 2000
CompletionActual
Aug 2004
Last update
Mar 16, 2009
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 16, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00654394
Lead sponsor
AstraZeneca
First posted
Apr 8, 2008
Start date
Jan 2000
Completion
Aug 2004
Last update
Mar 16, 2009

Study contacts

Tom Hatsukami
principal investigator · University of Washington, USA
Russell Esterline
study director · AstraZeneca

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rosuvastatin

Start the discussion